Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection-Reference-Cited by-同舟云学术

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

Published:2015-03 Issue:3 Volume:62 Page:533-540
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Agarwal Kosh,Fung Scott K.,Nguyen Tuan T.,Cheng Wendy,Sicard Eric,Ryder Stephen D.,Flaherty John F.,Lawson Eileen,Zhao Sally,Subramanian G. Mani,McHutchison John G.,Gane Edward J.,Foster Graham R.

Funder

Janssen Pharmaceuticals

Merck

Gilead Sciences

Roche

Gilead UK and Ireland Corporate Contributions

Novartis

British Microcirculation Society

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Hepatology

Reference30 articles.

1. Global epidemiology of hepatitis B virus;Custer;J Clin Gastroenterol,2004

2. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity;Ott;Vaccine,2012

3. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level;Chen;JAMA,2006

4. Risk and predictors of mortality associated with chronic hepatitis B infection;Iloeje;Clin Gastroenterol Hepatol,2007

5. EASL clinical practice guidelines: management of chronic hepatitis B virus infection;European Association for the Study of the Liver;J Hepatol,2012

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study;The Lancet Gastroenterology & Hepatology;2024-08

2. Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years;World Journal of Hepatology;2024-07-27

3. Clinical Efficacy and Safety of Long-Term Treatment of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate for Chronic Hepatitis B in Vietnam;Clinical and Translational Gastroenterology;2024-07-18

4. Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B;Journal of Medical Virology;2024-06-28

5. Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients;Frontiers in Medicine;2024-06-04